PEG-lipids (polyethylene glycol) have long been a critical component of lipid nanoparticles (LNPs), helping to stabilize nanoparticles, control particle size, and improve delivery efficiency. However, the development of anti-PEG antibodies can trigger accelerated blood clearance, thereby reducing therapeutic efficacy and limiting the potential for repeat dosing.
Cytofinity-LV replaces PEG-lipids with a non-immunogenic, naturally derived ganglioside lipid, enabling repeat dosing while reducing immunogenicity. Optimized for liver-targeted delivery, Cytofinity-LV provides a next-generation alternative to conventional liver-tropic LNP formulations.
Target Tissues:
- Liver
Potential Applications:
- Metabolic Diseases
- Rare Diseases
Supporting Data:
1. Cytofinity-LV LNPs can be tuned to target the liver
Luc-mRNA-loaded Cytofinity-LV LNPs exhibited predominant liver tropism